EU averts delays to new drug approvals
This article was originally published in SRA
Executive Summary
A potential 30-day delay to the issuing of new European Union marketing authorisations has been avoided after MEPs voted to shorten the statutory scrutiny period given to the European Parliament as part of the EU decision-making process1-3.